# The Biotech Growth Trust PLC (BIOG.L) fundamentals

Data as of 2026-09-08. LSE, United Kingdom. Sector: Financial Services. Price 1683p, market value 320 millionp.

## Valuation
- **P/E (trailing): 3.0×** (5-yr avg 353.2×, 3-yr avg 353.2×). The Biotech Growth Trust PLC trades at 3.0× trailing earnings, well below its own five-year average of 353.2×: cheap by its own standards. The Financial Services median in the September 2026 study was 13.1×.
- **Price / sales: 5.4×**. Each dollar of revenue is priced at 5.4×.
- **Price / book: 1.2×**. The shares trade at 1.2× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 6.4×**. Enterprise value is 6.4× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: -3.6%** (5-yr avg -0.0%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.
- **Earnings yield: 33.2%**. The inverse of the P/E: 33.2% of the price is earned each year.

## Profitability
- **Gross margin: 93.8%**. The Biotech Growth Trust PLC keeps 93.8% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 88.5%**. 88.5% of revenue is left after running the business, an exceptional level.
- **Net margin: 95.0%**. 95.0% of each dollar of sales reaches the bottom line.
- **Return on equity: 46.2%**. 46.2% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 17.7%**. Return on all capital, debt included, is 17.7%: comfortably above what that capital costs.
- **Return on assets: 15.7%**. Each dollar of assets produces 15.7% of profit; low single digits are normal for banks and insurers.

## Growth
- **Revenue growth (1 yr): 277.0%** (5-yr -7.7%/yr). Revenue grew 277.0% over the last year, against -7.7% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 313.0%** (5-yr 2.2%/yr). Earnings per share rose 313.0%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.
- **Cash and short-term investments: 0p**. Leverage ratios are shown differently for banks and insurers, whose balance sheets are built on deposits and reserves; use return on equity and the regulatory capital in the filings instead.

## Dividends
- **Dividend: none**. The Biotech Growth Trust PLC does not currently pay a dividend, but it returned 40.2% of its market value through buybacks over the last year.

## Price and momentum
- **Total return (1 yr): 83.1%** (YTD 43.8%, 3-mo 41.4%). The shares are up 83.1% over twelve months including dividends.
- **From 52-week high: -5.8%** (84.5% above the low). Trading 6% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 57**. An RSI of 57 is neutral.
- **Beta (1 yr): 0.46** (volatility 27%). Beta of 0.46 against the FTSE All-Share: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BIOG.L · Page: https://foliofundamentals.com/stocks/biog.l

Not investment advice.